TrialFrontiers in endocrinology2023

Long-term efficacy and safety of subcutaneous pasireotide alone or in combination with cabergoline in Cushing's disease.

Richard A Feelders et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.